



Institutional Biosafety Committee (IBC) Meeting Minutes

riceting rinduces					
Institution:	Wake Forest University Scl	hool of Medicine			
Meeting Date and Time:	July 16 th , 2025	uly 16 th , 2025			
Meeting Type:	Online via Microsoft Teams				
	Name	Role and Department	Atten	dance	
IBC Members Present:	Frank Marini, PhD	IBC Chair, WFIRM		□ Absent	
	Anthony Blaeser, PhD	IBC Vice Chair Musculoskeletal Department	⊠ Present	☐ Absent	
	Samuel Centanni, PhD	Voting Member, Translational Neuroscience	□ Present	□ Absent	
	Ji Hyun Kim, PhD	Voting Member, WFIRM	☐ Present	⊠ Absent	
	Elizabeth Palavecino, MD	Voting Member, Pathology		□ Absent	
	David Ornelles, PhD	Voting Member, Microbiology and Immunology	☐ Present	⊠ Absent	
	Marlena Westcott, PhD	Voting Member, Microbiology and Immunology	⊠ Present	☐ Absent	
	Brian Strittmatter, PharmD, MSCR	Voting Member, Pharmacy Clinical Trial Services, Pharmacy Manager	⊠ Present	□ Absent	
	Patrick McNutt, PhD	Voting Member, WFIRM,	□ Present	☐ Absent	
	Linda Metheny-Barlow, PhD	Voting Member, Radiation Oncology	☐ Present	⊠ Absent	
	Swapan Das, PhD, MSc	Voting Member, IM. Endocrinology & Metabolism	☐ Present	⊠ Absent	
	Caryn Gee Morse, MD, PhD	Voting Member, IM, Infectious Diseases	☐ Present	⊠ Absent	
	Drew Kiraly, MD	Voting Member, Translational Neuroscience	☐ Present	⊠ Absent	
	Robert Hampson, PhD	Voting Member, WFIRM	□ Present	☐ Absent	
	Farah Mougeot, PhD, MS	Voting Member, Translational Research – Oral Medicine	□ Present	⊠ Absent	
	Kimberly Woodward, MD, MPH	Voting Member, Pathology		☐ Absent	
	Paris Charilaou, MD, FACP	Voting Member, Gastroenterology and Hepatology	⊠ Present	☐ Absent	

	Yuming Jiang, MD, PhD	Voting Member, Radiation Oncology	☐ Present	⊠ Absent
	Dan Hurley	Local Non-Affiliated Community Member (Charlotte)	⊠ Present	□ Absent
	Jeanette Bennett	Community Member (Charlotte)	⊠ Present	□ Absent
	Kara Milton	Community Member (Winston Salem)	□ Present	□ Absent
	Adam Bray	Community Member (Winston Salem)	☐ Present	⊠ Absent
	Christpher Ohl, MD	Voting Member, IM, Infectious Diseases (Ad- Hoc)	☐ Present	⊠ Absent
	Scott Gamble, DVM	Voting Member, Animal Expert	□ Present	□ Absent
	Lisa Colvin	Voting Contact, IBC Administrator	□ Present	□ Absent
	Emylee Pedersen	Voting Contact, IBC Administrator	☐ Present	⊠ Absent
	Bernadette Menuey	Voting Member, Biosafety Officer	□ Present	□ Absent
	Jessica Baker	Voting Member, IACUC Representative	□ Present	□ Absent
	Katy Heide	Voting Member, EHS, Environmental Compliance	☐ Present	⊠ Absent
		Ex Officio W/O Vote		
	Suzy Mounsey	Animal Resources Program		□ Absent
	Gaye Hodges	Animal Resources Program	□ Present	□ Absent
	Stephen Fisenne	WFU Representative		☐ Absent
	Morgan Lawson	Environmental Health & Safety	□ Present	☐ Absent
	Jennifer Williams	Environmental Health & Safety	□ Present	□ Absent
	Paul Haliburton	EHS, AVP	□ Present	□ Absent
	Joseph Kim	AHWFB Teammate Health	□ Present	□ Absent
Quorum:	Yes			
Call to Order:	Called to order at 12:34			
Conflicts of Interest:	Chair reminded all members present to identify any conflicts of interest as protocols are reviewed. No COIs to disclose for this meeting.			
Review and Approval of Previous Meeting Minutes:	Motion to approve June min	utes by Dr. Marini, Second by	Dr. Westcott	
Review of Prior Meeting Business (if applicable):	None			

	New IBC Registrations and Amendments for Review		
PI Name:	Daunais, Jim		
Registration Number:	B25-W-009		
IBC Registration Title:	Neuroprotective potential of vaccination against influenza		
Project Overview:	Testing safety and comparative effectiveness of vaccination against influenza PR8.		
Applicable NIH Guidelines:	N/A		
Agent Description: e.g. virulence, pathogenicity, environmental stability	N/A		
Types of Manipulations:	N/A		
Source of nucleic (DNA/RNA) sequences: e.g. species	N/A		
Nature of nucleic acid sequences: e.g. structural gene, oncogene	N/A		
Host(s) and Vector(s):	N/A		
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	N/A		
Risk Assessment Discussion Points:	Team should clearly define procedures for animal handling related to MicroPET imaging. Teammates shipping or transporting infectious materials should complete appropriate training and package materials according to DOT guidelines		
Training:	Initial Biosafety Training Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) Emergency and Incident Response to Biohazard Spills and Releases		
Occupational Health Review (if applicable):	Influenza vaccination for lab staff.		
Biosafety Level: Animal Biosafety Level:	BSL/ABSL 1 for pre-challenge work BSL/ABSL 2 for challenge/ post-challenge work		
IBC Vote:	Approve pending modifications		
	New IBC Registrations and Amendments for Review		
PI Name:	Ahn, Bumsoo		

Registration Number:	B25-W-011
IBC Registration Title:	Interventions that cardiac muscle can mitigate skeletal and cardiac muscle weakness and atrophy in old and tumor-bearing rodents
Project Overview:	Commercially available murine tumor cells will be implanted in rodents with function to investigate effects of exercise and
Applicable NIH Guidelines:	pharmacological agents on sarcopenia and cancer cachexia. N/A
Agent Description: e.g. virulence, pathogenicity, environmental stability	N/A
Types of Manipulations:	N/A
Source of nucleic (DNA/RNA) sequences: e.g. species	N/A
Nature of nucleic acid sequences: e.g. structural gene, oncogene	N/A
Host(s) and Vector(s):	N/A
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	N/A
Risk Assessment Discussion Points:	All biological materials used in study are murine-derived. Testing for adventitious agents should be provided to the committee.
Training:	Initial Biosafety Training Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) Emergency and Incident Response to Biohazard Spills and Releases
Occupational Health Review (if applicable):	N/A
Biosafety Level: Animal Biosafety Level:	BSL 1/ABSL 1
IBC Vote:	Approved
	New IBC Registrations and Amendments for Review
PI Name:	Hsu, Wesley; Mott, Bryan
Registration Number:	B25-W-012

IBC Registration Title:	Combination Therapy of radiation, temozolomide and in glioblastoma
Project Overview:	This project will investigate the effect of a novel glioblastoma in murine models, its local microenvironment, and the subsequent response to existing treatment such as radiation therapy or temozolomide.
Applicable NIH Guidelines:	N/A
Agent Description: e.g. virulence, pathogenicity, environmental stability	Commercially available murine cell lines marked with GFP and firefly luciferase.
Types of Manipulations:	N/A
Source of nucleic (DNA/RNA) sequences: e.g. species	N/A
Nature of nucleic acid sequences: e.g. structural gene, oncogene	N/A
Host(s) and Vector(s):	N/A
Will a transgene be expressed? If so, what is the function of the protein that will be produced?	N/A
Risk Assessment Discussion Points:	None
Training:	Initial Biosafety Training Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) Emergency and Incident Response to Biohazard Spills and Releases
Occupational Health Review (if applicable):	N/A
Biosafety Level: Animal Biosafety Level:	BSL 1/ABSL 1
IBC Vote:	Approved pending modifications
Other	
New Business:	Post Approval Protocol Monitoring: Voorhees: EMN28-68284528MMY3005
Review of Incidents:	None
Lab Assessments Update:	N/A

	Training for members on new forms committee processes will be held July 23 rd @12:30 via Teams
Public Comments:	N/A
Adjournment:	Adjourned at 1:39 pm